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Abstract
The PI3K/AKT signaling pathway is aberrant in a wide variety of cancers. Downstream effectors
of AKT are involved in survival, growth, and metabolic-related pathways. In contrast,
contradictory data relating to AKT effects on cell motility and invasion, crucial pro-metastatic
processes, have been reported pointing to a potential cell type and isoform type-specific AKT
driven function. By implication, study of AKT signaling should optimally be conducted in the
appropriate intracellular environment. Prognosis in soft-tissue sarcoma (STS), aggressive
malignancies of mesenchymal origin, is poor reflecting our modest abilities to control metastasis,
an effort hampered by lack of insight into molecular mechanisms driving STS progression and
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dissemination. We examined the impact of the cancer progression relevant AKT pathway on the
mesenchymal tumor cell internal milieu. We demonstrate that AKT1 activation induces STS cell
motility and invasiveness at least partially via a novel interaction with the intermediate filament
vimentin. The binding of AKT (tail region) to vimentin (head region) results in vimentin Ser39
phosphorylation enhancing the ability of vimentin to induce motility and invasion while protecting
vimentin from caspase induced proteolysis. Moreover, vimentin phosphorylation was shown to
enhance tumor and metastasis growth in vivo. Insights into this mesenchymal-related molecular
mechanism may facilitate development of critically lacking therapeutic options for these
devastating malignancies.
Keywords
Soft-Tissue Sarcoma; AKT1; Vimentin; phosphorylation; Migration/Invasion
Introduction
The AKT kinase is a convergence point for multiple extracellular and other upstream signals
functioning as a master switch to generate a plethora of intracellular signals and responses.
Much evidence exists to support an important role for AKT in human cancer(Sulis &
Parsons, 2003). Downstream effectors of AKT are thought to be involved in survival,
growth, and metabolic-related pathways(Phung et al., 2006). In contrast, AKT effects on cell
motility and invasion, prerequisite processes for metastasis, while suggested, have been less
well elucidated(Grille et al., 2003). AKT is a family of isoforms including AKT1, AKT2,
and AKT3 sharing structural similarities. The expression patterns of the AKT isoforms
differ, as do their apparent biological activities(Sumitani et al., 2002). Although AKT1 and
AKT2 both play roles in cell motility and invasion, distinct and even opposing functions
have been observed. Several studies demonstrated that AKT1 attenuates invasive migration
of breast cancer cells (Irie et al., 2005; Liu et al., 2006; Yoeli-Lerner et al., 2005) while
AKT2 promoted migration in these cells in a growth factor-dependent manner(Irie et al.,
2005). Similar findings were seen in vivo in breast and ovarian cancer models(Arboleda et
al., 2003; Hutchinson et al., 2004; Maroulakou et al., 2007). In contrast, a recent study
identified AKT1 as inducing the migration of mammary epithelial tumor cells; AKT1
deficiency reduced migration and inhibited metastasis in an ErbB2-induced breast cancer
mouse model(Ju et al., 2007). Both AKT1 and AKT2 were found to enhance the
invasiveness of human pancreatic cancer cells(Tanno et al., 2001). Several potential direct
and indirect AKT targets have been identified as participatory in regulation of actin
cytoskeleton organization, cellular interaction with the extracellular matrix, expression of
motility genes, and establishment of cellular polarity(Miyazaki et al., 2007). These studies
point to the potential tumor/cell and AKT isoform type-specific function as relevant to
regulation of tumor cell migration/invasion. By implication, study of signaling pathways
should optimally be conducted in the appropriate intracellular environment to best
understand AKT complex effects.
Mesenchymal-derived soft-tissue sarcomas (STS) are rare compared to epithelial-origin
tumors and comprise more than 50 distinct histological subtypes. Genetically, STS are
classified into two major subgroups: those with simple karyotypes and specific genetic
alterations (translocations or point mutations; e.g. GIST), and a more prevalent cohort that
has complex, unbalanced aneuploid karyotypes (e.g. leiomyosarcoma). STS disseminate
hematogenously, particularly to the lungs; these metastases are a major determinant of the 5-
year 50% overall STS survival rate, a survivorship now stagnant for nearly 50 years.
Chemotherapy is used to control dissemination, but few drugs have efficacy in STS(Clark et
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al., 2005). The lack of effective systemic therapy is thus the major unresolved STS clinical
dilemma.
Recent molecular insights have led to new therapy for some simple-karyotype STS. In
contrast, the molecular diversity and intricacy of genetically complex STS has impeded a
comparable awareness of molecular deregulations driving sarcomagenesis, progression, and
metastasis needed for therapeutic progress in this latter group. Studies of epithelial cancers
indicate that both invasion and metastasis may depend on the acquisition of a mesenchymal
phenotype by the incipient cancer cell(Yang & Weinberg, 2008). Therefore, it is logical to
propose that STS, originating from mesenchymal cells, might possess inherent capacities for
enhanced migration/invasion. Identifying the molecular basis for these processes could
provide a heretofore unexploited basis for development of critically needed therapies for
STS.
While not extensively explored, evidence points to possible involvement of AKT in STS
development and progression. Increased pAKT expression in a large panel of complex
karyotype STS has recently been reported(Hernando et al., 2007) and a correlation between
pAKT expression and subsequent tumor recurrence and patient survival was
described(Tomita et al., 2006). Using a conditional PTEN knockout mouse model, a critical
role for AKT in leiomyosarcoma development was shown(Hernando et al., 2007). We have
recently demonstrated a significant impact of AKT inhibition on STS growth in vitro and in
vivo(Zhu et al., 2008). However, little is known about the contributions of AKT to STS
migration and invasion, or about possible AKT downstream targets that are affected in the
unique mesenchymal STS intracellular milieu. To bridge this knowledge gap, we evaluated
the contribution of AKT, specifically the AKT1 isoform, to complex-karyotype STS cell
migration and invasion. We identified vimentin (Vim), an intermediate filament highly
expressed in mesenchymal cells, as a novel AKT1 downstream target. AKT1 binds to Vim,
resulting in Vim phosphorylation and activation, findings of potential significance in
establishing novel therapeutics for STS.
Results
AKT1 signaling contributes to STS migration and invasion
The effect of AKT on STS cell migration/invasion was first determined. Activation of AKT
(via EGF stimulation) induced a significant increase in migration/invasion (p<0.05; Figure
1A and S1A). However, this approach is not specific, in that EGFR stimulation induces
multiple downstream signaling pathways. Seeking more specificity, we determined the
impact of pAKT blockade on these processes. STS cells were treated for 2h with the PI3K
inhibitor LY294002 (10μM), the AKT inhibitor A674563 (A563; 1μM), or DMSO as a
control. After discontinuation of the drugs viable cells were examined in migration/invasion
assays; a significant decrease was observed (p<0.05; Figure 1A and S1A). In contrast, no
significant effect on migration/invasion was observed with a MEK inhibitor (UO126;
Figures S1A and S1B).
Next, primary cultures of normal smooth muscle cells and normal human dermal fibroblasts
(mesenchymal cells exhibiting minimal constitutive AKT activity, thus enabling the study of
AKT mutants’ effects independent of endogenous AKT impact; Figure S1C) were
transiently transfected to express WT-AKT, dominant-negative AKT (AAA), and
constitutively active AKT (DD; transfection efficiency was >70%), functional impact were
confirmed by pGSK3β (Figures 1B and S1D). Control (pcDNA3-transfected) cells exhibited
only minimal migration/invasion capacity. Overexpression of WT-AKT induced a minimal
increase in cell migration/invasion; AKT-AAA inhibited cell motility/invasion. In contrast,
AKT-DD increased the number of migrating and invading cells approximately five- and six
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fold, respectively (p<0.001; Figures 1C and S1D). The effects of activated AKT on GSK3β
phosphorylation and cell migration/invasion were not sensitive to PI3K or MEK/ERK
pharmacological blockade (Figure 1C).
The expression of AKT isoforms was examined in a panel of human STS cell lines and
primary cultures (see Figure S2A for primary culture details). We have previously
demonstrated that STS express pAKT under serum and serum free conditions through a
multitude of potential upstream mechanisms(Zhu et al., 2008). Here we show that STS cells
express pAKT (Ser473) and all three AKT isoforms to varying levels (Figure 2A); however,
only AKT1 was found to be constitutively phosphorylated (Figure 2B). Furthermore, EGF
stimulation resulted in marked AKT1 phosphorylation (Figure 2C); AKT3 phosphorylation
was also seen to a lesser extent but there was no evidence for AKT2 phosphorylation. This
selective effect was not specific for EGFR activation and was also seen after HGF
stimulation (data not shown). In contrast, EGF stimulation induced AKT2 phosphorylation
in the epithelial-origin MDA-231 cell line. This differential effect was further confirmed via
nonradioactive AKT1 and AKT2 kinase assays (Figure 2C). AKT1 knockdown significantly
inhibited the migration/invasion of STS cells (p<0.05); no significant comparable effects
were seen after AKT2 knockdown (Figure 2D). Interestingly, forced expression of AKT2
into STS cells does result in its constitutive and inducible phosphorylation (Figure S2B) and
is able to rescue the effects of AKT1 knockdown on STS cell migration/invasion (Figure
S2C). Transfection of AKT2-DD into STS cells results in enhanced migration/invasion
(p<0.05; Figure S2D). Together, these data suggest that AKT2 expression as compared to
AKT1 is relatively low in STS.
Vimentin is a novel AKT1 binding partner
Next, we sought to identify novel STS-related AKT1 binding proteins. A proteomics-based
approach was utilized; AKT1 coimmunoprecipitated (co-IP) proteins were analyzed by mass
spectrometry to identify putative AKT1 protein binding partners. Several bands from AKT1
immunoprecipitate were selected for further sequencing and 10 proteins were identified
(Figure 3A, Table S1). All identifications, done primarily by MALDI-TOF mass
spectrometry, were validated by sequencing with MS-MS. Interaction with AKT1 was
further confirmed via IP/WB for three of the proteins: DDX5, GRP75, and Vim as well as
for the known AKT1 binding partners MDM2 and GSK3β (Figure 3A).
We focused our investigations on Vim being the major intermediate filament in
mesenchymal cells. As expected, Vim expression was seen in all evaluated human STS
samples, primary cell cultures, and established cell lines (Figure 3B). Interaction between
AKT1 and Vim was identified in all STS immunoprecipitates tested (Figure 3C).
AKT2:Vim interaction was also identified although to a lower degree most probably
reflecting low AKT2 expression levels. To demonstrate the interaction of AKT1 and Vim
within the context of the intact STS cell we have utilized three assays: 1) double
immunoflorescence, demonstrating co-localization of endogenous AKT1 and Vim; 2) co-
transfection of DsRed-AKT1 and Vim-GFP, demonstrating co-localization of the transfected
proteins via live cell microscopy; and, 3) protein-fragment complementation assay
(RePCA): protein-protein interaction was demonstrated by positive fluorescent expression
evaluated by microscopy and flow cytometry (Figure S3A–C). This interaction was further
confirmed in an experimental model by overexpressing Vim and AKT1 in cells expressing
low (HEK293) or no (MCF7) Vim (see Figure S3D&E). Lastly, using a an in vitro co-
sedimentation assay we found that AKT1 co-sendiments with the polymerized vimentin
fraction (Fig S3F).
To identify the potential interacting sites on AKT1 and Vim, GST-fused full-length AKT1
and specific AKT1 domains as well as full-length Vim and specific Vim domains were
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produced (Figure 4A). GST-AKT1-FL was able to pull down Vim from crude STS cell
lysates (Figure 4B). Similarly, GST-AKT1-TAIL, but not other domains, resulted in Vim
pull-down. Similarly, AKT1 was pulled down by GST-VIM-FL and GST-VIM-HEAD, but
not by other Vim domains (Figure 4C). However, data obtained from intact cells do not
confirm direct AKT-Vim binding, as intermediary proteins might be involved and AKT-
Vim co-IP could be a result of their dual interaction with other proteins. To confirm direct
AKT- Vim interaction, an in vitro protein binding assay was conducted. GST- Vim proteins,
purified as above, were evaluated for binding to a commercially available AKT1 protein.
GST-AKT1 proteins were also incubated with recombinant Vim protein. These in vitro
protein binding assays confirmed the direct interaction between AKT1 tail domain and Vim
head domain (Figure 4D).
Vimentin is a novel AKT1 kinase target
Next, we evaluated whether AKT activation results in vimentin phosphorylation. We first
evaluated protein extracts from primary human STS samples (see Figure S4A); all samples
expressed pAKT to varying degrees (Figure 5A). Protein extracts were immunoprecipitated
for Vim and a WB for anti-phosphorylated AKT substrate (PAS) antibody was conducted.
This antibody, raised against an AKT phosphorylation consensus sequence, detects
phosphorylated AKT target sites. Vim was recognized by the PAS antibody in all samples to
varying degrees (Figure 5A). Vim immunoprecipitates from STS cells stimulated with EGF,
with or without pretreatment with LY294002 or rapamycin (an mTORC1 inhibitor), were
subjected to WB using PAS antibody (Figure 5B). Vim was recognized by the PAS
antibody, and Vim phosphorylation increased in a time dependent manner after AKT
activation and decreased after PI3K blockade but not after the inhibition of mTORC1 and S6
kinase. Similarly, double immunoflorescence studies suggested colocalization of Vim and
PAS in STS cells. This colocalization was abrogated after short treatment (4h) with
LY294002 (Figure S4B). Furthermore, AKT1 knockdown markedly decreased Vim
phosphorylation while AKT2 did not (Fig 5B). In contrast to STS cells, no constitutive
AKT-induced Vim phoshorylation was observed in normal mesenchymal cells (Figure S1E).
However, overexpression of AKT1-DD in normal cells did induce Vim phosphorylation
(Figure S1F).
Two-dimensional PAGE WB with an antibody to Vim further supported Vim
phosphorylation by AKT1 (Figure S4C). Protein lysate extracted from cells after treatment
with LY294002 or A563 exhibited differential migration of Vim on the isoelectric point axis
compared to that of untreated cells, suggesting Vim post-translational modification (most
likely related to changes in phosphorylation state) induced by AKT inhibition.
To confirm that Vim is potentially a direct AKT substrate an in vitro AKT kinase assay was
conducted. GST-VIM was phosphorylated by activated AKT1 but not by AKT kinase-dead
control (Figure 5C). To dissect out the exact AKT phosphorylation site(s) in Vim, an in vitro
kinase assay was conducted using cold ATP. Vim separated on SDS-PAGE after incubation
with or without active AKT1, was identified via Coomassie blue staining. Corresponding
bands were isolated, excised, and digested into tryptic peptides, which were in turn
subjected to three complementary phosphoproteomics MS-based methods: MALDI TOF/
TOF, liquid chromatography (Bodenstine & Welch)/MS/MS, and multiple reaction
monitoring (MRM) (Table S2 and Figures 5D&S4D–G). These studies identified Ser39 of
Vim as a potential AKT1 phosphorylation target; no other AKT1-induced phosphorylation
sites were found.
We next mutated the GST-VIM-FL construct at Ser39 and Ser325 (another Motif Scan
(http://scansite.mit.edu/) predicted AKT phosphorylation site, Table S3) to create GST-
VIM-S39A and GST-VIM-S325A constructs and utilized corresponding GST fusion
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proteins in an AKT1 in vitro kinase assay. Constitutively activated AKT1 induced the
phosphorylation of GST-VIM and GST-VIM-S325A, but not GST-VIM-S39A (Figure 5E).
Similarly, IP using an anti-GFP antibody after transfection of STS cells with either VIM-
GFP or VIMS39A-GFP constructs showed that Ser39 mutation abrogates AKT1-induced
Vim phosphorylation (Figure 5F).
AKT1-induced STS cell migration and invasion are mediated by vimentin
We sought to evaluate the possible functional biological implications of AKT1-Vim
interaction and phosphorylation. MTS assays demonstrated that Vim knockdown resulted in
a small (22% ± 5%; Figure 6A) reduction in growth of STS cells within 24hr; markedly
more pronounced was the reduction in STS cell migration/invasion (p<0.01). Next, MCF7
cells (lacking endogenous vimentin) were transfected with Vim, AKT1-DD, WTVim, Vim
S39A, or both AKT1-DD and WT or S39A Vim (Figure 6B); as previously shown(Hendrix
et al., 1997) WT Vim induced an increase in migration/invasion, whereas mutated Vim
S39A or AKT1-DD overexpression alone did not significantly affect these processes. Co-
transfection of WT Vim and AKTDD resulted in marked vimentin phosphorylation and a
significant (p<0.05) increase in migration/invasion, while transfection of the
unphosphorylatable mutated Vim S39A together with AKT-DD did not enhance these
processes. To further evaluate the importance of AKT1-induced Vim Ser39
phosphorylation, MCF7 cells were transfected with WT or S39D Vim constructs. The
phosphomimetic Vim had a more pronounced effect on MCF7 migration/invasion than
WTVim (p<0.05; Figure 6C).
Next, a rescue experiment in STS cells was conducted where endogenous Vim was first
knocked-down using anti-Vim antisense morpholino oligomers (Figure 6D); cells were
transfected with either WTVim, Vim-S39A, or Vim-S39D. WTVim and Vim-S39D were
capable of, at least partially, rescuing the migratory/invasive phenotype of Vim knocked-
down cells (p<0.005), whereas Vim-S39A had only minimal effects (p>0.05). Lastly,
SKLMS1 cells stably transfected to overexpress Vim S39D/GFP exhibited significantly
larger tumors and a higher experimental metastasis rate when injected to SCID mice as
compared to Vim S39A/GFP transfected cells (Table S4).
AKT inhibition induces vimentin proteolysis
The effect of AKT inhibition on Vim in STS cells was next evaluated. A decrease in the
total level of full length Vim was observed secondary to both the AKT inhibitor A563 and
the PI3K inhibitor LY294002 and was accompanied by an increase in cleaved Vim products
and increased activated caspase-3 levels (Figure 7A–B). In contrast, neither the MEK
inhibitor UO126 nor the mTORC1 inhibitor rapamycin affected Vim expression or induced
caspase activation in STS cells (Figure 7B). Previous data suggest that the initial step in Vim
proteolysis is its cleavage by caspase 3(Byun et al., 2001). Caspase activity blockade using
Z-VAD but not the proteosome inhibitor MG132 significantly decreased LY294002-induced
Vim proteolysis (Figure 7C). Use of frozen tissues from our previously published animal
experiments (Zhu et al., 2008), in which HT1080 xenografts were treated with A563,
demonstrated that AKT inhibition–induced Vim proteolysis and caspase 3 activation occurs
in vivo as well (Figure 7D).
The possible role of Ser39 phosphorylation in protecting Vim from proteolysis was
evaluated. Anti-Vim morpholino oligos were used to knockdown native Vim and WT or
mutated (S39A or S39D) Vim were forcefully re-expressed. Treatment with LY294002
resulted in marked proteolysis of WTVim or S39A-Vim, whereas no cleavage was noted in
cells expressing the S39D-Vim (Figure 7E). Similarly, LY294002 treatment resulted in the
development of granular GFP-expressing aggregates in cells transfected with GFP-tagged
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WTVim or GFP-tagged S39A-Vim, but to a markedly lesser degree in cells transfected with
GFP-tagged S39D-Vim (Figure 7F).
Discussion
Our studies identified that AKT1 is constitutively active in STS cells. Moreover, cytokine
stimulation induces AKT1 and AKT3 phosphorylation to varying degrees, but not AKT2.
The specific mechanisms resulting in this observed differential isoform activation are not
known; results here suggest that this may be the consequence of low AKT2 expression
levels in STS cells. Other factors such as subcellular localization, differential
compartmentalization, selectivity of upstream kinases or phosphatases, and perhaps
association with unique scaffold proteins or binding partners affecting their accessibility to
their upstream effectors might also play be in effect. While not extensively studied in cells
of mesenchymal origin, there is some evidence to support the contention that AKT1
enhances migration and invasion. For example, AKT1 was found to promote migration and
invasion of fibroblasts and endothelial cells(Ackah et al., 2005; Kanda et al., 2004). One
study evaluated the effect of AKT1 activation on sarcoma cells; overexpression of
constitutively active membrane-targeted AKT1 or kinase-dead AKT1 mutants in human
fibrosarcoma cells demonstrated that AKT1 enhances motility and invasion, possibly by
regulating the expression of MMP9(Kim et al., 2009). Our results using a knockdown
approach substantiate and expand this initial observation; taken together, it is possible to
conclude that activation of AKT1 (but not AKT2) enhances STS tumor cell motility and
invasion. AKT inhibitors are in various development stages; several pan AKT blockers
already being evaluated in human clinical trials. Efforts are under way to develop isoform-
specific inhibitors to decrease off-target effects and hopefully reduce drug-related toxicity.
Based on the results presented here, AKT1 is a particularly attractive candidate for STS
therapy.
The observed dependence of AKT function on cancer type, cell type, and AKT isoform can
potentially be attributed to unique downstream substrates expressed in a particular
intracellular microenvironment. Here we identified Vim as a potential AKT downstream
target in STS. Vim is one of the most widely expressed mammalian intermediate filament
proteins. In adults, Vim is present in all mesenchymal cells and tissues(Broers et al., 1989)
and is therefore frequently used as a differentiation marker. Insights from genetically
engineered Vim knockout mice suggest that the physiological structural role of Vim in
quiescent mesenchymal cells is potentially redundant and can be carried out by different cell
components; Vim knockout mice are viable and do not exhibit overt phenotypes(Colucci-
Guyon et al., 1994). This observation is an important consideration if Vim is to be further
investigated as a therapeutic target. However, several lines of investigation suggest that Vim
has functions that extend beyond simple mechanical and structural roles, including
involvement in adhesion, migration and cell survival(Bhattacharya et al., 2009; Eckes et al.,
1998; Hendrix et al., 1997; McInroy & Maatta, 2007; Menet et al., 2001). “Hijacking” of
normal physiological processes is a hallmark of cancer; a multitude of potential Vim
functions raise the possibility that it could contribute to the pro-tumorigenic, pro-metastatic
properties of STS cells. Although the exact mechanisms underlying Vim function and its
activation are mostly unknown, a variety of studies suggest that Vim phosphorylation is a
key regulator of these effects. Phosphorylation plays a major role in regulating Vim
structure, dynamic assembly, and interaction with many intracellular structures (including
mitochondria and nuclei) and individual proteins (Pittenger et al., 2008). Vim contains a
highly complex phosphorylation pattern involving a multitude of kinase-specific
sites(Nelson & Traub, 1983) and is recognized as a substrate for several kinases, including
RhoA kinase(Sin et al., 1998), protein kinase C (PKC), cGMP kinase, Yes, Raf-1, PAK, and
Aurora B (Goto et al., 1998). For example, PKCε-mediated Vim phosphorylation at N-
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terminal residues was found to induce cell motility via integrin recycling and trafficking to
the cell membrane(Ivaska et al., 2005). To our knowledge, the studies presented here are the
first to demonstrate an association between AKT and Vim. Furthermore, direct AKT-
induced phosphorylation of Vim at Ser39 was identified; alanine mutation of Ser39
perturbed the ability of Vim to induce migration and invasion, whereas expression of mutant
Vim with an acidic residue replacing Ser39 enhanced Vim function both in vitro and in vivo.
It is of note that the AKT motif found in vimentin is RXXS/T and not the classical
RXRXXS/T AKT consensus site; this motif has been identified in a large panel of potential
AKT substrates (See Table S3)(Fang et al., 2007; Gu et al., 2006; Luo et al., 2007; Qi et al.,
2006). Being a non-classical AKT phosphorylation motif, we cannot rule out that the
observed AKT induced phosphorylation of vimentin in STS cells of functional consequences
is not a result of an indirect effect due to AKT activation of AGC kinases that are possibly
recruited to vimentin secondary to AKT:vimentin binding and in turn phosphorylate
vimentin. Whatever is the case, taken together, our findings identify a novel mechanism of
AKT function relevant to STS cells and add an additional downstream target to those with
which AKT interacts.
AKT is known for its pro-survival effects; AKT blockade results in significant apoptosis in a
multitude of cancer models, including STS(Zhu et al., 2008). Data presented here offer a
potential novel mechanism for AKT blockade induced apoptosis affecting Vim-expressing
cells. A role for Vim in apoptosis was recently elucidated(Byun et al., 2001). Vim undergoes
rapid proteolysis upon diverse pro-apoptotic stimuli, including ionizing radiation, Fas,
TRAIL, TNFα, and tamoxifen. This Vim proteolysis occurs secondary to caspase pathway
activation, resulting in cleavage of Vim by multiple caspases at several sites (Asp85,
Asp259, and Asp429;(Byun et al., 2001). It is possible that Vim proteolysis and collapse
contribute to many of the morphological manifestations of apoptosis, including cellular
rounding, nuclear condensation, and packaging of the debris of dying cells into apoptotic
bodies. Furthermore, Vim proteolysis releases potential pro-apoptotic proteolytic fragments
that can markedly enhance apoptosis. For example, the generation of a short N-terminal
cleavage product (amino acids 1-85) was shown to play an active pro-apoptotic role
(Morishima, 1999). A positive feedback loop is suggested whereby activated caspases
induce the cleavage of Vim and these cleavage products in turn activate caspases to amplify
apoptosis. To our knowledge, AKT blockade-induced Vim proteolysis has not been
previously described. AKT inhibition is known to induce the activation of caspases; our
results elucidate the mechanism by demonstrating that AKT blockade induces caspase-
dependent Vim proteolysis in vitro and in vivo. Our results also suggest that AKT-induced
Vim phosphorylation protects Vim (to some extent) from caspase proteolysis, suggesting a
potential pro-survival effect of AKT. Future clinical trials evaluating the effect of AKT
inhibitors on STS could assess the utility of measuring Vim cleavage as a marker of
apoptosis/therapeutic efficacy.
In summary, many key regulatory roles played by AKT in STS cells could be at least
partially mediated through its interaction with and consequential phosphorylation of Vim.
Vim could therefore potentially be selectively targeted for STS therapy. This previously
unexplored biology has important therapeutic implications and merits further investigation.
Materials and Methods
Cell Lines and Reagents
A list of cell lines, human cell strains (including isolation and characterization), and culture
conditions is provided in the Supplemental Experimental Procedures. A comprehensive list
of all commercial antibodies, inhibitors, cytokines, constructs and transfection procedures
are described in detail in Supplementary data.
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Cell Growth
Cell growth assays were done with a CellTiter96 Aqueous Non-Radioactive Cell
Proliferation Assay kit (Promega), per manufacturer instructions. Absorbance was measured
at 490 nm; absorbance of treated cells is graphically presented as a percentage of control cell
absorbance.
Migration and Invasion Assays
Migration and invasion assays were conducted as described previously(Liu et al., 2006);
further detail is provided in supplementary data.
Western Blotting and Coimmunoprecipitation
WB analysis, coimmunoprecipitation and two-dimensional PAGE western blot analysis
were performed by standard methods. Brief details are provided in the supplementary data.
Mass Spectrometry
In-Gel Trypsin Digestion methodology is described in supplementary data. MALDI-TOF
MS was used for AKT1 binding partners protein identification (detailes are provided in
supplementary data). Three complementary MS-based methods were used for
phosphoproteomics: MALDI TOF/TOF, liquid chromatography (Bodenstine & Welch)/MS/
MS, and multiple reaction monitoring (MRM). Further details can be found in
supplementray data.
GST Fusion Protein Pull-Down and In Vitro Protein Binding Assays
Expression of GST and GST-tagged full-length Vim, Vim fragments, full-length AKT1, and
AKT1 fragments was induced in E. coli BL21, and proteins were purified by immobilization
on glutathione-Sepharose-4B beads (GE Healthcare). Further detail is provided in the
Supplemental data. For GST fusion protein pull-down assays, 50 μl of beads (5 μg of
immobilized protein) were incubated with 500–1,000 μg of whole-cell lysates in 1% NP-40
buffer for 4 h at 4°C. For in vitro protein binding assays, 10 μl of beads (1 μg of
immobilized protein) were incubated with commercially available recombinant human Vim
(1 μg) or AKT1 (1 μg) in a 1% NP-40 buffer for 2 h at 4°C. Beads were spun down and
washed with cold 1% NP-40 in 1x PBS (1 ml each), boiled in 10 μl of 4x SDS gel loading
buffer, and subjected to SDS–PAGE followed by western blotting.
Nonradioactive AKT Kinase Assay and In Vitro AKT Kinase Assay
Nonradioactive Akt Kinase Assay Kit providing all the reagents necessary to measure AKT
1 or 2 kinase activity was purchased from Cell Signaling. Immobilized AKT antibodies were
used to immunoprecipitate AKT 1 or w from cell extracts. Then, a kinase assay was
performed using GSK-3 Fusion Protein as a substrate in the presence of 200 μM of cold
ATP. Phosphorylation of GSK-3 was measured by WB, using pGSK-3 Ab.
Constitutively activated AKT1 or kinase dead AKT were incubated with 10 μl of GST
affinity matrix bead-purified wild-type or mutated Vim proteins (details provided in the
Supplemental Experimental Procedures) in the presence of 5 μCi of [γ-32P]ATP, 50 mM
cold ATP, and 1.5x AKT1 kinase buffer (75 mM Tris (pH 7.4), 25 mM MgCl2, 2 mM
dithiothreitol, 0.1 mM NaVO3, 1.5 μM proteinase inhibitor, and 1.5 mg/ml bovine serum
albumin) for 30 min at room temperature. The reaction mixture was spun down, and the
beads were washed with PBS. After the addition of 10 μl of 4x SDS gel loading buffer,
reaction products were resolved by SDS-PAGE and γ-32P-labeled proteins were visualized
by autoradiography. The experiment was repeated excluding [γ-32P]ATP (only cold ATP
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was added) for submission of Vim to phosphoprotein mass spectrometry analysis. Bands
were identified via Coomassie blue staining.
Animal Experiments
All animal procedures and care was approved by the Institutional Animal Care and Usage
Committee of UTMDACC and are described in supplementary data.
Statistical Analysis
All experiments were repeated at least three times to ensure reproducibility. Cell
proliferation, migration, and invasion assays were repeated three times, and means ± SD
were calculated. Two sample t tests were used to assess the differences. Significance was set
at p≤0.05. Statistical considerations relating to mass spectrometry studies are described in
the supplementary data section. Differences in xenograft growth in vivo were assessed using
a two-tailed Student’s t test. Significance was set at p≤0.05. All computations were
performed with SAS 9.1 (SAS Institute) and S-PLUS 7.0 (Insightful).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. AKT phosphorylation enhances STS cell migration and invasion
A. EGF induces AKT phosphorylation (WB for pS473) in SKLMS1 cells and enhances
migration/invasion. Inhibitors of PI3K (LY=LY294002) and AKT (A563) block AKT
downstream signaling (evaluated by pGSK3β) and abrogate EGF-induced SKLMS1
migration/invasion; B. Normal human smooth muscle cells (HC-SMC) were transfected to
overexpress HA-tagged wild type AKT, dominant negative AKT (AAA), and activated AKT
(D); pGSK3β levels confirm the function of the overexpressed proteins. Overexpression of
AKT-DD significantly increased the number of migrating and invading cells (p<0.001); C.
Effects of AKT-DD on HC-SMC downstream signaling and cell migration and invasion is
independent of PI3K or MEK blockade. [Graphs represent the average of three repeated
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experiments ±SEM; * depict statistically significant effects (p<0.05); pAKT WB in all
panels refer to pS473] (See also Figure S1)
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FIGURE 2. AKT1 is constitutively and inducibly activated in STS cells; its inhibition abrogates
migration and invasion
A. STS cell lines and high-grade human STS primary cultures express pAKT (pS473) and
all three AKT isoforms to varying levels (WB); B. IP for AKT1, AKT2 and AKT3 and
corresponding WB demonstrate that only AKT1 is constitutively phosphorylated in STS
cells; C. IP of AKT1, 2, and 3 in STS cells after or without treatment with EGF
demonstrates induction of AKT1 and AKT3 phosphorylation but not of AKT2. In contrast,
EGF stimulation induces the phosphorylation of AKT2 in MDA231 cells. This differential
effect was further demonstrated via an AKT kinase assay using GSK-3 fusion protein as a
substrate; D. SKLMS1 cells were transiently transfected with SMARTpool siRNA (20nM;
two different pools were used) targeting AKT1 or AKT2; a target-specific knockdown was
observed (WB). siRNA Knockdown of AKT1 but not of AKT2 significantly inhibits STS
cell migration/invasion (p<0.05). [Graphs represent the average of three repeated
experiments ±SEM; * depict statistically significant effects (p<0.05); pAKT WB in all
panels refer to pS473] (See also Figure S2)
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FIGURE 3. Vimentin Is a Novel AKT1 Binding Partner
A. SDS-PAGE gel obtained for AKT1 co-immunopreciptiates (normal mouse IgG was used
as control). Marked bands were excised, and subjected to identification by mass
spectrometry (see protein details in Table S1). Interaction of proteins 5*, (Vim), 7* (DDX5),
and 8* (GRP75) with AKT1 (band 6*) were further confirmed by AKT1 IP/WB. Interaction
of AKT1 with the its known partners MDM2 and GSK3β in STS cells is shown as control;
B. Human STS samples (right upper panel), primary cell cultures (left upper panel), and cell
lines (lower panel) highly express Vim; C. IP/WB and reverse IP/WB further confirmed the
interaction between AKT1 (and to a lesser extent AKT2, most probably due to the lower
expression level of this AKT isoform in STS) and Vim in human STS tissues (left panels),
primary cell cultures (mmiddle panel), and cell lines (right panel). (MFH1 = malignant
fibrous histiocytoma; LMS1&2= leiomyosarcoma; uncl = unclassified pleomorphic
sarcoma). (See also Figure S3)
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FIGURE 4. AKT1 C-Terminal tail domain interacts with vimentin head domain
A. full-length AKT1 (AKT1-FL), AKT1 pleckstrin homology domain (AKT1-PH), AKT1
catalytic domain (AKT1-CAT), AKT1 C-terminal tail domain (AKT1-TAIL), full-length
Vim (VIM-FL), Vim head domain (VIM-HEAD), Vim coiled-coil domain (VIM-CC), and
Vim tail domain (VIM-TAIL) cDNA fragments were cloned into the pGEX4T1 vector to
produce GST fusion proteins in E. coli BL21; B. GST-pull down assay indicated that the
GST-AKT1-FL and GST-AKT1-TAIL domains interact with Vim in SKLMS1 cells; C.
GST-pull down assay indicated that GST-VIM-FL and GST-VIM-HEAD domain interact
with AKT1 in SKLMS1 cells; D. In vitro protein binding assays indicated that the GST-
VIM-HEAD and the GST-AKT1-TAIL domains directly interact.
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FIGURE 5. Vimentin is a novel AKT1 Kinase downstream target
A. Primary human high grade STS (HGS 1-8) express pAKT (pS473; WB); Vim in these
samples is recognized by the phospho-AKT substrate antibody (PAS antibody #9611, Cell
Signaling; IP/WB) suggesting AKT-induced Vim phosphorylation; B. EGF induced pAKT
enhances Vim phosphorylation in a time dependent manner in STS cells as indicated by
increase in PAS detection on Vim. This effect was abrogated upon treatment with
LY294002 but not by rapamycin. siRNA knockdown of AKT1 but to a lesser degree of
AKT2 results in decreased Vim phosphorylation (demonstrated by Vim IP/PAS WB); C. An
in vitro AKT1 kinase assay demonstrates the incorporation of [γ-32P]ATP into GST-VIM in
the presence of activated AKT1 kinase but not AKT1 kinase dead protein (AKT1-AAA); D.
An in vitro AKT1 kinase assay was performed in the presence of cold ATP and two bands
corresponding to Vim treated with AKT1 or without AKT1 were subjected to mass
spectrometry; shown is the product ion spectra for the of 2+ charge state of the
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TYSLGSALRPSTSR Vim peptide (788.39). LC/MS/MS data-dependent acquisition; the
product ion spectra were searched against the Swissprot database using Mascot (Table S2).
The 49 Da (2+) change designated in red indicates that a hydrogen phosphate group
(HPO42-) and a water molecule (H2O) were lost from the peptide. y and b ions are indicated
in red; the inset reveals a 69 Da change associated with the loss of a phospho-serine versus
the 87 Da changes in ion mass associated with the loss of a non-phospho serine: E. In vitro
AKT1 kinase assay demonstrated that constitutively activated AKT1 induces the
phosphorylation of GST-VIM and GST-VIM-S325A but not GST-VIM-S39A; F. Anti-GFP
IP after transfection of STS cells with either VIM-GFP or VIMS39A-GFP constructs
demonstrated that Ser39 mutation abrogates AKT-induced Vim phosphorylation. [pAKT
WB in all panels refer to pS473] (See also Figure S4)
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FIGURE 6. AKT1-induced STS cell migration and invasion are mediated, at least in part, by
vimentin
A. Vim knockdown resulted in a small (15% ± 5%) reduction in SKLMS1 growth but a
marked decrease in migration/invasion (p<0.01); B. MCF7 cells were transfected with
AKT1 DD, Vim, VimS39A individually or in combination. Over-expression of vimentin
and to a higher degree vim in conjuncture with AKTDD resulted in the detection of
phosphorylated vimentin using Vim IP/PAS WB. WT Vim overexpression in MCF7 cells
increased migration/invasion, whereas AKT1-DD overexpression alone did not significantly
affect these processes. Moreover, co-transfection of AKT1-DD and WT Vim resulted in the
most pronounced effect (p<0.05). In contrast transfection of mutated Vim S39A did not
enhance migration/invasion and these processes were not significantly impacted by the co-
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transfection of AKT-DD and Vim S39A; C. Forced expression of Vim-S39D enhanced the
migration/invasion of MCF7 cells as compared to WT Vim (p<0.05); D. Endogenous Vim
was knocked down in STS cells (using anti-Vim morpholino) and cells were then transfected
with either pcDNA, WT-Vim, Vim-S39A, or Vim-S39D (WB). WT-Vim and Vim-S39D
were capable of at least partially rescuing the migratory and invasive phenotype of the Vim
knockdown cells (p<0.005), whereas Vim-S39A had only minimal effects (p>0.05). [Graphs
represent the average of three repeated experiments ±SEM; * depict statistically significant
effects (p<0.05); pAKT WB in all panels refer to pS473]
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FIGURE 7. AKT inhibition induces caspase dependent vimentin proteolysis in STS cells
A. Treatment with A563 resulted in a dose dependent decrease in total Vim and an increase
in Vim cleavage products; B. Similarly, a dose dependent decrease in full length Vim and its
increased proteolysis as well as caspase 3 activation was seen after LY294002 treatment but
not with UO126 or rapamycin; C. Caspase activity blockade using Z-VAD markedly
decreased LY294002-induced Vim proteolysis; no such effect was observed using the
proteosome inhibitor MG132; D. Increase in Vim proteolysis and caspase 3 activation was
found in protein extracts from HT1080 xenografts treated with A563; E. SKLMS1 cells after
Vim knockdown (using morpholino oligos) were transfected with pcDNA (control), WT or
mutated (S39A or S39D) Vim. Treatment with LY294002 resulted in marked proteolysis of
WT Vim or S39A VIM, whereas no cleavage was noted in cells expressing the S39D VIM;
F. LY294002 treatment resulted in the development of granular GFP-expressing aggregates
in SKLMS1 cells transfected with GFP-tagged Vim or GFP-tagged S39A-Vim, but not in
cells transfected with GFP-tagged S39D-Vim. [pAKT WB in all panels refer to pS473] (See
also Figure S5)
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